RED BANK, N.J., March 4, 2021 /PRNewswire/ -- Provention
Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to
intercepting and preventing immune-mediated disease, today
announced that management will participate in two upcoming virtual
investor conferences in March.
H.C. Wainwright Global Life Sciences Conference
Andrew Drechsler, Provention
Bio's Chief Financial Officer will provide a corporate update at
the H.C. Wainwright Global Life Sciences Conference. The
webcast will be available beginning Tuesday,
March 9, 2021, at 7:00 am E.T
and can be accessed by visiting the Events and Webcasts section of
the Company's website:
http://investors.proventionbio.com/events.
Oppenheimer & Co. 31st Annual Healthcare
Conference
Additionally, the company announced that Ashleigh Palmer, Provention Bio's Chief
Executive Officer and Co-Founder will participate in a fireside
chat presentation at the Oppenheimer & Co. 31st Annual
Healthcare Conference on Tuesday, March 16,
2021 at 1:10 pm E.T. The
fireside chat will be webcast live and can be accessed by visiting
the Events and Webcasts section of the Company's
website: http://investors.proventionbio.com/events.
Both webcasts will be archived on the Company's website for 30
days following the presentation.
About Provention Bio, Inc.:
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical
company focused on advancing the development of investigational
therapies that may intercept and prevent debilitating and
life-threatening immune-mediated disease. The Biologics License
Application (BLA) for teplizumab, its lead investigational drug
candidate, for the delay or prevention of clinical type 1 diabetes
in at-risk individuals, has been filed by the U.S. Food and Drug
Administration (FDA). The Company's pipeline includes additional
clinical-stage product candidates that have demonstrated in
pre-clinical or clinical studies proof-of-mechanism and/or
proof-of-concept in other autoimmune diseases, including celiac
disease and lupus. Visit www.ProventionBio.com for more
information and follow us on Twitter: @ProventionBio.
Internet Posting of Information:
Provention Bio, Inc. uses its
website, www.proventionbio.com, as a means of disclosing
material nonpublic information and for complying with its
disclosure obligations under Regulation FD. Such disclosures will
be included on the Company's website in the "News" section.
Accordingly, investors should monitor this portion of the Company's
website, in addition to following its press
releases, SEC filings and public conference calls and
webcasts.
Investor Contacts:
Robert
Doody, VP of Investor Relations
rdoody@proventionbio.com
484-639-7235
Sam Martin, Argot Partners
sam@argotpartners.com
212-600-1902
Media Contact:
Lori Rosen, LDR Communications
lori@ldrcommunications.com
917-553-6808
View original content to download
multimedia:http://www.prnewswire.com/news-releases/provention-bio-to-present-at-two-upcoming-virtual-investor-conferences-301240159.html
SOURCE Provention Bio, Inc.